Volume 5, Issue 3 (Summer 2024)
J Vessel Circ 2024, 5(3): 0-0 |
Back to browse issues page
Ethics code: IR.KAUMS.MEDNT.REC.1402.117
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ebrahim Kouchaki1 E, Masoud S A, Rahimi H, Shahverdi A, shahverdi S, Alshavi Z. Evaluation of the Therapeutic Outcomes of Tissue Plasminogen Activator and Antiplatelet Therapy in Patients with Ischemic Stroke. J Vessel Circ 2024; 5 (3)
URL: http://jvessels.muq.ac.ir/article-1-300-en.html
URL: http://jvessels.muq.ac.ir/article-1-300-en.html
Ebrahim Ebrahim Kouchaki1 
, Seyed Ali Masoud , Habibollah Rahimi , Alireza Shahverdi , Somaye Shahverdi * 1, Zeinab Alshavi
, Seyed Ali Masoud , Habibollah Rahimi , Alireza Shahverdi , Somaye Shahverdi * 1, Zeinab Alshavi
Abstract: (20 Views)
Background and Aim: Stroke is one of the most common causes of disability and mortality worldwide, with ischemic stroke accounting for the majority of cases. Timely treatment with thrombolytic agents like alteplase and antiplatelet drugs such as aspirin can improve clinical outcomes. This study aimed to compare the therapeutic outcomes of alteplase and aspirin in patients with ischemic stroke.
Materials and Methods: This analytical cross-sectional and prospective cohort study was conducted at Shahid Beheshti Hospital in Kashan in 2023. Patients were divided into two groups based on the time of hospital arrival and NIHSS scores: the alteplase group (treatment within 3 hours of symptom onset) and the aspirin group (treatment after 12 hours). Demographic, clinical, and laboratory variables, as well as treatment outcomes (NIHSS and MRS scores), were compared at 72 hours and 90 days post-treatment. Data were analyzed using SPSS version 22 and appropriate statistical tests.
Results: The mean age of patients was 59.3 ± 8.22 years in the alteplase group and 57.7 ± 6.6 years in the aspirin group. Significant improvement in NIHSS and MRS scores was observed in both groups, but the alteplase group showed greater improvement at both 72 hours and 90 days post-treatment (P=0.001). Mortality rates did not differ significantly between the groups, but adverse effects such as intracranial hemorrhage were more frequent in the alteplase group.
Conclusion: Treatment with alteplase compared to aspirin can lead to significant improvement in clinical outcomes for ischemic stroke patients, particularly when administered within the 3- to 4.5-hour window after symptom onset. However, careful management of adverse effects, such as intracranial hemorrhage, is essential. Increasing public awareness about the importance of timely hospital admission can enhance the efficacy of thrombolytic therapies.
Materials and Methods: This analytical cross-sectional and prospective cohort study was conducted at Shahid Beheshti Hospital in Kashan in 2023. Patients were divided into two groups based on the time of hospital arrival and NIHSS scores: the alteplase group (treatment within 3 hours of symptom onset) and the aspirin group (treatment after 12 hours). Demographic, clinical, and laboratory variables, as well as treatment outcomes (NIHSS and MRS scores), were compared at 72 hours and 90 days post-treatment. Data were analyzed using SPSS version 22 and appropriate statistical tests.
Results: The mean age of patients was 59.3 ± 8.22 years in the alteplase group and 57.7 ± 6.6 years in the aspirin group. Significant improvement in NIHSS and MRS scores was observed in both groups, but the alteplase group showed greater improvement at both 72 hours and 90 days post-treatment (P=0.001). Mortality rates did not differ significantly between the groups, but adverse effects such as intracranial hemorrhage were more frequent in the alteplase group.
Conclusion: Treatment with alteplase compared to aspirin can lead to significant improvement in clinical outcomes for ischemic stroke patients, particularly when administered within the 3- to 4.5-hour window after symptom onset. However, careful management of adverse effects, such as intracranial hemorrhage, is essential. Increasing public awareness about the importance of timely hospital admission can enhance the efficacy of thrombolytic therapies.
Type of Study: Research |
Subject:
vascular neurological diseases
Received: 2025/03/8 | Accepted: 2025/04/14 | Published: 2024/12/31
Received: 2025/03/8 | Accepted: 2025/04/14 | Published: 2024/12/31
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Owned by Qom University of Medical Sciences
Published by Qom University of Medical Sciences Press
eISSN: 2717-0357
Email: jvessels[at]muq.ac.ir
j.vessels.circul[at]gmail.com
